Geoffrey J. Markowitz

Geoffrey J. Markowitz

Auto-generated profile, based on publicly available information

Geoffrey J. Markowitz

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2018 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
NANasser K. Altorki
Nasser K. Altorki
GMGeoffrey J. Markowitz
Geoffrey J. Markowitz
DGDingcheng Gao
Dingcheng Gao
JPJeffrey L. Port
Jeffrey L. Port
ASAshish Saxena
Ashish Saxena
VMVivek Mittal
Vivek Mittal

1 September 2012 in Cancer Cell
Verified
Journal Article
Closed access
PYPengyuan Yang
Pengyuan Yang
QLQi-Jing Li
Qi-Jing Li
YFYuxiong Feng
Yuxiong Feng
YZYun Zhang
Yun Zhang
GMGeoffrey J. Markowitz
Geoffrey J. Markowitz
XWXiao-Fan Wang
Xiao-Fan Wang

1 January 2020 in Cell Reports
Verified
Journal Article
Open access
SYShira Yomtoubian
Shira Yomtoubian
SLSharrell B. Lee
Sharrell B. Lee
AVAkanksha Verma
Akanksha Verma
FIFranco Izzo
Franco Izzo
GMGeoffrey Markowitz
Geoffrey Markowitz
VMVivek Mittal
Vivek Mittal
Epigenetic changes are increasingly being appreciated as key events in breast cancer progression. However, breast cancer subtype-specific epigenetic regulation remains poorly investigated. Here we report that EZH2 is a leading candidate of epigenetic modulators associated with the TNBC subtype and that it predicts poor overall survival in TNBC patients. We demonstrate that specific pharmacological or genetic inhibition of EZH2 catalytic activity impairs distant metastasis. We further define a specific EZH2high population with enhanced invasion, mammosphere formation, and metastatic potential that exhibits marked sensitivity to EZH2 inhibition. Mechanistically, EZH2 inhibition differentiates EZH2high basal cells to a luminal-like phenotype by derepressing GATA3 and renders them sensitive to endocrine therapy. Furthermore, dissection of human TNBC heterogeneity shows that EZH2high basal-like 1 and mesenchymal subtypes have exquisite sensitivity to EZH2 inhibition compared with the EZH2low luminal androgen receptor subtype. These preclinical findings provide a rationale for clinical development of EZH2 as a targeted therapy against TNBC metastasis.

1 September 2014 in National Science Review
Verified
Journal Article
Open access
PDF file
PYPengyuan Yang
Pengyuan Yang
GMGeoffrey J. Markowitz
Geoffrey J. Markowitz
XWXiao-Fan Wang
Xiao-Fan Wang
In contrast to a majority of cancer types, the initiation of hepatocellular carcinoma (HCC) is intimately associated with a chronically diseased liver tissue, with one of the most prevalent etiological factors being hepatitis B virus (HBV). Transformation of the liver in HBV-associated HCC often follows from or accompanies long-term symptoms of chronic hepatitis, inflammation and cirrhosis, and viral load is a strong predictor for both incidence and progression of HCC. Besides aiding in transformation, HBV plays a crucial role in modulating the accumulation and activation of both cellular components of the microenvironment, such as immune cells and fibroblasts, and non-cellular components of the microenvironment, such as cytokines and growth factors, markedly influencing disease progression and prognosis. This review will explore some of these components and mechanisms to demonstrate both underlying themes and the inherent complexity of these interacting systems in the initiation, progression, and metastasis of HBV-positive HCC.

2 March 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
CZChanglu Zhang
Changlu Zhang
YGYanan Gao
Yanan Gao
CDChengzhi Du
Chengzhi Du
GMGeoffrey J. Markowitz
Geoffrey J. Markowitz
JFJing Fu
Jing Fu
PYPengyuan Yang
Pengyuan Yang
Hepatitis B–associated hepatocellular carcinoma (HCC) is often accompanied by severe vascular invasion and portal vein tumor thrombus, leading to a poor prognosis. However, the underlying mechanism of this disease remains obscure. In this study, we demonstrate that the hepatitis B virus (HBV)–encoded gene HBx induces high IL8 production through MEK–ERK signal activation, leading to enhanced endothelial permeability to facilitate tumor vascular invasion. In a vascular metastatic model using a tail vein injection in a transgenic mouse with selective expression of human CXCR1 in the endothelium, activation of the IL8–CXCR1 cascade by overexpression of IL8 in tumor cells dramatically enhanced liver metastasis. Mechanistically, IL8 selectively induced GARP-latent-TGFβ in liver sinusoidal endothelial cells and subsequently provoked preferential regulatory T-cell polarization to suppress antitumor immunity. Collectively, these findings reveal a hepatitis B–associated IL8–CXCR1 signaling axis that mediates vascular invasion and local microenvironmental immune escape of HCC to induce intrahepatic metastasis, which may serve as potential therapeutic targets for HBV-associated HCC. Significance: This study identifies a hepatitis B–induced IL8/CXCR1/TGFβ signaling cascade that suppresses antitumor immunity and enhances metastasis in hepatocellular carcinoma, providing new potential targets for therapeutic intervention.

7 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
XXXin Xu
Xin Xu
YZYun Zhang
Yun Zhang
JJJeff Jasper
Jeff Jasper
ELErik Lykken
Erik Lykken
PAPeter B. Alexander
Peter B. Alexander
XWXiao-Fan Wang
Xiao-Fan Wang
MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer